saracatinib (AZD0530) / AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
saracatinib (AZD0530) / AstraZeneca
2011-002157-64: A randomised phase II double blind (neither patient or doctor know which treatment they are taking) trial looking to see if giving patients saracatinib in addition to usual aromatase inhibitors will prevent or delay disease resistance in post menopausal women with advanced breast cancer.

Ongoing
2
140
Europe
Saracatinib, AZD0530,
Common Services Agency, AstraZeneca
Advanced breast cancer
 
 
2019-003324-20: A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOP Een onderzoek ter beoordeling van de veiligheid, verdraagbaarheid en effecten op abnormale botvorming van het onderzoeksgeneesmiddel AZD0530 (saracatinib) bij patiënten met FOP

Not yet recruiting
2
20
Europe
Saracatinib, AZD0530, Tablet
VU University Medical Center, Innovative Medicines Initiative EU, AstraZeneca
Fibrodyplasia Ossificans Progressiva (FOP), Genetic condition which causes abnormal formation of bone at abnormal locations such as in the muscles, tendons and ligaments., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
STOPFOP, NCT04307953: Saracatinib Trial TO Prevent FOP

Recruiting
2
20
Europe
AZD0530 Difumarate, Saracatinib, Matching placebo
Amsterdam UMC, location VUmc, Royal National Orthopaedic Hospital NHS Trust, Klinikum Garmisch-Patenkirchen, University of Oxford, Brigham and Women's Hospital, AstraZeneca, Innovative Medicines Initiative
Fibrodysplasia Ossificans Progressiva
05/25
05/25
2010-021447-41: SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer

Ongoing
1/2
158
Europe
saracatinib, AZD0530,
NHS Greater Glasgow Health Board, Glasgow University
Metastatic, castration-resistant prostate cancer
 
 
STOP-IPF, NCT04598919: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Active, not recruiting
1/2
49
US
Saracatinab, Placebo
National Jewish Health, Yale University, Icahn School of Medicine at Mount Sinai, AstraZeneca, National Center for Advancing Translational Sciences (NCATS), Baylor University, International Center for Health Outcomes and Innovation Research
Idiopathic Pulmonary Fibrosis (IPF)
09/24
06/25

Download Options